Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 2/3 1

Status

Completed 52Terminated 24Recruiting 7Active not recruiting 6Withdrawn 5Not yet recruiting 3Unknown 2

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 7

Conditions

Lymphoma, Large B-Cell, Diffuse 39Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Mantle-Cell 19Lymphoma, Follicular 18Lymphoma 17Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, B-Cell 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 3Leukemia 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Heart Failure 2Epstein-Barr Virus Infections 2Dendritic Cell Sarcoma, Interdigitating 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Thalassemia 1Sjogren's Syndrome 1

Interventions

Rituximab 7zanubrutinib 6venetoclax 4ibrutinib 3Dexamethasone 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2Bendamustine Hydrochloride 2pirtobrutinib 1obinutuzumab 1Positron-Emission Tomography 1Lenalidomide 1Exercise 1Diet 1CT-P10 1Bortezomib 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Waldenstrom Macroglobulinemia × Rituximab × Clear all
NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05099471 2026-05-05

VIWA-1

University of Ulm

Phase 2 Recruiting
80 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT06561347 2026-03-31

ZEBRA

Massachusetts General Hospital

Phase 2 Recruiting
55 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05914662 2024-08-28

ZBR

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
42 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT04061512 2024-05-10

RAINBOW

University College, London

Phase 2/3 Recruiting
148 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT03697356 2023-10-06

Ballondor

Kosin University Gospel Hospital

Phase 2 Recruiting
54 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡